ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA) announced it will release its financial results for Q3 2022 on November 9, 2022, after market close. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results and company updates. ADMA specializes in manufacturing and marketing plasma-derived biologics for immunocompromised patients. It currently offers three FDA-approved products including ASCENIV™ and BIVIGAM® for primary immunodeficiency. The company operates a licensed facility in Boca Raton, Florida, and is committed to supporting niche patient populations.

Positive

• ADMA has three FDA-approved plasma-derived biologics on the market for treating immune deficiencies.
• The upcoming financial results announcement may provide insights into the company's growth and market performance.

Negative

• None.

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call, participants may register for the call here to receive the dial-in numbers and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call). A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:
Skyler Bloom
Senior Director, Business Development & Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com 

FAQ

When will ADMA Biologics report Q3 2022 financial results?

ADMA Biologics will report its Q3 2022 financial results on November 9, 2022, after market close.

What time is the ADMA Biologics conference call?

The conference call for ADMA Biologics is scheduled for November 9, 2022, at 4:30 p.m. ET.

What products does ADMA Biologics offer?

ADMA Biologics offers three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®.

How can I access the ADMA Biologics conference call?

Participants can register for the conference call through ADMA's investor website to receive dial-in details and a unique PIN.